Table 2.
Longitudinal fluctuations in serum anti-EBNA-1 and anti-VCA IgG levels in relapsing remitting multiple sclerosis (RRMS) patients, considered as a whole, during 21 months of Natalizumab treatment.
| Time point (sample) | Serum anti-EBNA-1 IgG levels (AU) median, IQR |
Serum anti-VCA IgG levels (AU) median, IQR |
|---|---|---|
| T0 (n = 16) | 273750, 160073–411955 | 107720, 44682–151729 |
| T3 (n = 19) | 264992, 133546–372122 | 82629, 45782–134306 |
| T6 (n = 19) | 299852, 149020–415994 | 103548, 52914–158579 |
| T9 (n = 19) | 272304, 151911–433509 | 100277, 73889–172901 |
| T12 (n = 20) | 234446, 159224–369656 | 112400, 59598–195399 |
| T15 (n = 18) | 218906, 164613–356031 | 110428, 88676–276036 |
| T18 (n = 19) | 230182, 136390–410000 | 145650, 98579–310823 |
| T21 (n = 18) | 239703, 163733–366165 | 115988, 77566–379377 |
AU = arbitrary units; EBNA-1 = Epstein-Barr nuclear antigen-1; IQR = interquartile range; SD = standard deviation; T0 = baseline; T3 = the 3rd month; T6 = the 6th month; T9 = the 9th month; T12 = the 12th month; T15 = the 15th month; T18 = the 18th month; T21 = the 21st month; VCA = Epstein-Barr viral capsid antigen.